Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Adaptive Biotechnologies Corp (ADPT) Q2 2024 Earnings Call Transcript Highlights: Strong MRD Revenue Growth and Improved Margins
Adaptive Biotechnologies Corp (ADPT) reports significant MRD revenue growth and improved sequencing margins, despite challenges in immune medicine revenue. Aug 02, 2024
GuruFocus Research Biotechnology
Vir Biotechnology Inc (VIR) Q2 2024 Earnings Call Transcript Highlights: Strategic Restructuring and Promising Pipeline Developments
Vir Biotechnology Inc (VIR) reports significant cost-saving measures and strategic pipeline focus amid workforce reduction and financial commitments. Aug 02, 2024
GuruFocus Research Biotechnology
Ultragenyx Pharmaceutical Inc (RARE) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Performance and Increased Guidance
Ultragenyx Pharmaceutical Inc (RARE) reports robust Q2 2024 results with increased revenue guidance and significant advancements in clinical trials. Aug 02, 2024
GuruFocus Research Biotechnology
Arbutus Biopharma Corp (ABUS) Q2 2024 Earnings Call Transcript Highlights: Financial Stability and Promising Clinical Results Amid Workforce Reduction
Arbutus Biopharma Corp (ABUS) extends cash runway into Q4 2026 while advancing key clinical trials despite significant workforce cuts. Aug 02, 2024
GuruFocus Research Biotechnology
Regeneron Pharmaceuticals Inc (REGN) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Robust Pipeline Amidst Rising Expenses
Regeneron Pharmaceuticals Inc (REGN) reports a 12% increase in total revenue and significant growth in key product sales, while navigating increased operating expenses and competitive pressures. Aug 02, 2024
GuruFocus Research Biotechnology
Alnylam Pharmaceuticals Inc (ALNY) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Updated Guidance
Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with significant year-over-year growth and raises full-year revenue guidance. Aug 02, 2024
GuruFocus Research Biotechnology
Aurinia Pharmaceuticals Inc (AUPH) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Positive Cash Flow
Aurinia Pharmaceuticals Inc (AUPH) reports significant year-over-year revenue growth and positive free cash flow in Q2 2024, despite challenges in gross margin and patient screening rates. Aug 02, 2024